+ +

•  

   

     Western blot analysis of TNF beta expression in TNF beta recombinant protein.    

  
  

The fibrinogen-like protein 2 (FGL2) antibody targets FGL2. a glycoprotein belonging to the fibrinogen-related protein family. FGL2 exists in two forms: a membrane-bound protein expressed on endothelial and immune cells, and a soluble secreted protein. Membrane-bound FGL2 regulates immune responses by binding to inhibitory receptors like FcγRIIB, suppressing T-cell activation and promoting regulatory T-cell (Treg) function. Secreted FGL2 acts as a prothrombinase, inducing thrombin generation and fibrin deposition, which links coagulation and inflammation. Dysregulated FGL2 expression is implicated in viral infections (e.g., hepatitis, COVID-19), autoimmune diseases, and cancer.

FGL2 antibodies, including monoclonal and polyclonal variants, are research tools to modulate FGL2 activity. In autoimmune contexts, blocking FGL2 antibodies may restore immune tolerance by inhibiting its immunosuppressive effects. Conversely, in cancer, FGL2 antibodies could counteract tumor immune evasion by disrupting FGL2-mediated T-cell suppression. Studies also explore FGL2 as a biomarker for disease progression or therapeutic response. Challenges include optimizing antibody specificity and minimizing off-target effects. Current research focuses on preclinical models, with potential for clinical translation in immune-mediated diseases and coagulopathies.